Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

WuXi Facility Passes FDA API Manufacture Inspection

Published: Wednesday, August 20, 2014
Last Updated: Wednesday, August 20, 2014
Bookmark and Share
Company's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) passed an FDA inspection in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug.

This represents the first FDA inspection of STA’s facilities for the manufacture of an API. Last year, STA’s manufacturing operations passed an inspection by the FDA for the manufacture of an advanced intermediate. 

STA’s integrated platform of services, extending from process research to research manufacturing to commercial manufacturing, helps the company’s clients move their new chemical entities through preclinical and clinical development to global commercial launch. 

“We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, Chairman and CEO of WuXiPharmaTech. “These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization.” 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WuXi PharmaTech Receives First Approval from Japanese Regulatory Authorities
STA subsidiary receives approval for the manufacture of the GMP intermediate of a branded commercial drug.
Thursday, September 03, 2015
WuXi PharmaTech and TruTag Complete Successful Testing of Authentication Solution
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Thursday, August 20, 2015
WuXi PharmaTech to Build New Cell Therapy Manufacturing Facility
Facility is designed for CAR T cells and other cancer immunotherapies.
Friday, March 20, 2015
WuXi Opening Offices in Boston and San Francisco
New offices will give access to innovative companies in the world's two leading biotech hubs.
Friday, December 19, 2014
WuXi PharmaTech Laboratory Testing Division Expands in U.S.
XenoBiotic acquisition expands LTD’s presence in North America.
Wednesday, October 08, 2014
WuXi PharmaTech Begins Operation of New HPAPI Laboratory
Adds HPAPI processing capabilities at Shanghai lab.
Thursday, May 29, 2014
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
Company announces that construction has been completed on a new biologics biosafety testing facility in Suzhou.
Tuesday, May 13, 2014
WuXi Breaks Ground on New Cell Therapy Manufacturing Facility
The facility in Philadelphia is expected to become operational in the second quarter of 2015.
Thursday, May 01, 2014
WuXi PharmaTech Announces Management Appointments
Dr. Steve Yang joins Company as EVP and chief operating officer and Edward Hu named chief investment officer and remains chief financial officer.
Thursday, April 17, 2014
WuXi and PRA Form Joint Venture
The agreement will offer a broad platform of Phase I-IV clinical trial services in China, Hong Kong and Macau.
Tuesday, January 01, 2013
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos